Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • cladribine

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    TRIMTECH Therapeutics establishes Scientific Advisory Board

    Alessio Ciulli has been appointed as Chair of the board

    - PMLiVE

    Roche shares promising data from Alzheimer’s disease development portfolio

    The company is planning to initiate phase 3 studies of trontinemab in early AD this year

    - PMLiVE

    Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

    The immune-mediated disease affects more than 2.9 million people worldwide

    - PMLiVE

    UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

    It is hoped that the test could be available for widespread UK use in the coming years

    - PMLiVE

    Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

    SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

    - PMLiVE

    Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

    The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

    - PMLiVE

    GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

    The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

    - PMLiVE

    Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    GSK to explore link between Shingrix and dementia risk in new UK research collaboration

    More than 55 million people worldwide are currently living with the neurodegenerative disease

    - PMLiVE

    Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

    The neurological disorder affects more than 150,000 people in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links